34% revenue in Q3
70% gross margin (down from 75%)
Net income of 44.6 million (vs. 4.3 million last year)
Operating cash flow of 181 million (vs. 14.1 million last year)
Outlook:
"Heart Assist" is set to enter the market in the EU, Canada, and Australia.
PMA approval for the U.S. is still pending for 2027.
"Liver Assist" also has an application pending in the U.S., with market entry planned for early 2028.
